Article info

PDF

Original article
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

Authors

  1. Correspondence to Professor Gamal Shiha, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Dakahlia 35516, Egypt; g_shiha{at}hotmail.com
View Full Text

Citation

Shiha G, Esmat G, Hassany M, et al
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

Publication history

  • Received December 20, 2017
  • Revised March 7, 2018
  • Accepted March 29, 2018
  • First published April 17, 2018.
Online issue publication 
March 07, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.